Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy
Authors:
- 18 January 2013
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 168 (4) , 898-899
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Livedoid vasculopathy secondary to high levels of lipoprotein(a)British Journal of Dermatology, 2011
- Livedoid Vasculopathy in a Pediatric Patient With Elevated Lipoprotein(a) Levels: Prompt Response to Continuous Low-Molecular-Weight HeparinArchives of Dermatology, 2010
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip ArthroplastyNew England Journal of Medicine, 2008
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee ArthroplastyNew England Journal of Medicine, 2008
- Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarinJournal of the American Academy of Dermatology, 2008
- Livedoid VasculopathyArchives of Dermatology, 2006
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitorJournal of Thrombosis and Haemostasis, 2005